Trial NCT01503632

Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

Major Program(s) or Research Group(s)

  • Community Oncology and Prevention Trials
  • NCI Community Oncology Research Program
  • Supportive Care and Symptom Management

Sponsor

Children's Oncology Group

Status

Active, not recruiting

ClinicalTrials.gov ID

For more information, see ClinicalTrials.gov NCT01503632

This randomized phase III trial studies compliance to a mercaptopurine treatment intervention
compared to standard of care in younger patients with acute lymphoblastic leukemia that has
had a decrease in or disappearance of signs and symptoms of cancer (remission). Assessing
ways to help patients who have acute lymphoblastic leukemia to take their medications as
prescribed may help them in taking their medications more consistently and may improve
treatment outcomes.

Intervention

Behavioral Intervention, Compliance Monitoring, Laboratory Biomarker Analysis, Mercaptopurine, Questionnaire Administration, Standard Follow-Up Care

Condition

Childhood Acute Lymphoblastic Leukemia in Remission

Investigators

Smita Bhatia

See list of participating sites